Biodel to Report Second Quarter Fiscal Year 2010 Financial Results on May 6, 2010

DANBURY, Conn.--(BUSINESS WIRE)-- Biodel Inc. (Nasdaq: BIOD) will issue its second quarter fiscal year 2010 financial results on May 6, 2010. Following the release of the company's financial results, Biodel's senior management will host a conference call to discuss the results and provide an update on the company's progress.

May 6, 2010 schedule:

4:00 pm EDT:

  Q2 fiscal year 2010 results will be
distributed by Business Wire
 

4:15 pm EDT:

Conference call participants should dial:
+1 (877) 303-8028 (United States) or
+1 (760) 536-5167 (International)
 

4:30 pm EDT:

Conference call begins

Interested parties may access a live audio webcast of the conference call in the investor section of Biodel's website at http://www.biodel.com. The audio webcast will be archived and available for replay through the website.

About Biodel

Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes. Biodel's product candidates are developed using VIAdel(TM) technology, which reformulates existing FDA-approved peptide drugs. Biodel's new drug application for its most advanced product candidate, VIAject(R), has been accepted for review by the U.S. Food and Drug Administration with a Prescription Drug User Fee Act action date of October 30, 2010. Earlier stage product candidates include VIAtab(TM), a sublingual tablet formulation of insulin, a line of basal insulins and a stabilized formulation of glucagon. For further information regarding Biodel, please visit the company's website at www.Biodel.com.

BIOD-G



CONTACT:

The Trout Group LLC
Seth D. Lewis, +1-617-583-1308

KEYWORDS:   United States  North America  Connecticut

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical

MEDIA:

Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.